Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer

Trial Profile

Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CRTCOESC
  • Most Recent Events

    • 06 Jun 2017 Interim results (n=86), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jul 2016 Grade 3/4 acute toxicities added as primary endpoint ; hence trial focus changed from TU to TU + AR. minimum age changed from 45 years to 18 years.
    • 16 Nov 2015 Planned End Date changed from 1 Dec 2022 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top